Publications by authors named "Saili Zeng"

Non-small-cell lung cancer (NSCLC) is a high-risk type of lung cancer. This study aims to improve the diagnostic efficacy of NSCLC through the combined detection of miR-375 and short-stature homeobox 2 (SHOX2) methylation. Patients with NSCLC (n = 121) and benign lung disease (BLD) (n = 121) were included.

View Article and Find Full Text PDF

In general, non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) mutations respond to tyrosine kinase inhibitors (TKIs). However, most patients experience resistance within 1-2 years after treatment. The histological explanation for the acquired resistance is that malignant transformation occurs during cancer treatment.

View Article and Find Full Text PDF

In recent years, immune checkpoint inhibitors were successfully introduced to various of cancer therapy. Pembrolizumab, an antibody to programmed cell death-1 (PD-1), which is was approved for treatment of any adult or pediatric, unresectable or metastatic solid tumor. However, just as chemotherapeutics, immune checkpoint inhibitors have many side effects, which are named as immune-related adverse events.

View Article and Find Full Text PDF

Purpose: Endometriosis (EMT) is a chronic benign disease with high prevalence. This study investigated the diagnostic value of serum miR-17-5p, miR-424-5p, and their combined expressions for EMT.

Methods: Total 80 EMT patients of reproductive age who underwent laparoscopy or laparotomy and were confirmed by pathological examination were included as the study subjects, and another 80 healthy women of reproductive age receiving gynecological examination and ultrasonography with no pelvic abnormalities were selected as the control group.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to evaluate the impact of simvastatin on pulmonary fibrosis in rats, specifically looking at markers of fibrosis and vascular integrity (VE-cadherin, vimentin, and alpha-SMA).
  • A total of 60 male rats were divided into four groups: one control group, one fibrosis group (bleomycin treated), and two simvastatin treatment groups (5 mg and 10 mg).
  • Results showed that simvastatin significantly reduced fibrosis markers and increased VE-cadherin levels compared to the fibrosis group, particularly at the highest dose (10 mg) after 28 days of treatment.
View Article and Find Full Text PDF